HK Stock Market Move | XD INC (02400) rose more than 6% again, the company has been repurchasing shares for 22 consecutive days, with a total repurchase amount of approximately 170 million Hong Kong dollars.
Heartbeat Company (02400) rose over 6% again, at the time of publication, up 6.21% to HK$46.16, with a turnover of HK$89.263 million.
XD INC (02400) rose by more than 6%, reaching a 6.21% increase by the time of publication, with a price of 46.16 Hong Kong dollars and a trading volume of 89.263 million Hong Kong dollars.
In terms of news, XD INC announced that on July 15th, the company repurchased 180,000 shares, amounting to 7.7598 million Hong Kong dollars. Data shows that since June 12th, the company has conducted repurchases for 22 consecutive days, totaling 3.7312 million shares repurchased with a cumulative amount of 1.70 billion Hong Kong dollars. So far this year, the company has conducted 95 repurchases, repurchasing a total of 9.5558 million shares with a cumulative amount of 5.69 billion Hong Kong dollars.
Western points out that XD INC's self-developed games in multiple categories continue to deliver, successfully creating two long-term potential products with "Heartbeat Town" and "Torchlight: Infinite"; TapTap platform continues to expand boundaries, not just a distribution channel for mobile games, but also important for developers in building a comprehensive ecological infrastructure, forming an ecological closed loop; TapADN+TapTap PC+TapTap Maker opens up the platform ceiling, optimistic about the company's scarce platform value and self-developed game potential for long-term success.
Related Articles

JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
.png)
RECOMMEND





